FDA scolds drugmaker for touting ‘misleading’ comparison with generics
The Impact of Misleading Medicine Claims: A Closer Look at Regulations The recent scolding by the FDA of Edenbridge Pharmaceuticals over misleading promotional materials highlights the tension between brand-name and generic medications. The agency pointed out inaccuracies in a promotional display that claimed Hemady, a treatment for multiple myeloma, was more effective due to better … Read more